Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.

Ocio, Enrique MBringhen, SaraMartinez-Lopez, JoaquinSan-Miguel, JesusOliva, StefaniaRodriguez-Otero, PaulaLe Roux, NadiaDong, YvonneDoroumian, SeverineMacé SandrineMateos, Maria-Victoria2024-09-162024-09-162023-02Hemasphere . 2023 ;7(2):e829.https://hdl.handle.net/20.500.12105/23106engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.Attribution-NonCommercial-NoDerivatives 4.0 Internacional3675151372e82910.1097/HS9.00000000000008292572-9241HemaSphereopen access